Virtual Library

Start Your Search

  • WCLC 2016

    17th World Conference on Lung Cancer

    Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria

    Presentation Date(s):  
    • Dec 4 - 7, 2016
    • Total Presentations: 2466

    To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.

    Presentations will be available 24 hours after their live presentation time

Filter Results:

Show Only Available Presentations

  • +

    P3.02a - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 37
    • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P3.02a-001 - Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC

      14:30 - 14:30  |  Author(s): L. Horn

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    P3.02b - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 126
    • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P3.02b-115 - Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib

      14:30 - 14:30  |  Author(s): S.M. Gadgeel

      • Abstract

      Loading...

  • +

    P3.02c - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 103
    • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P3.02c-050 - IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

      14:30 - 14:30  |  Author(s): H. Wakelee

      • Abstract

      Loading...